Wealth Enhancement Trust Services’s Rocket Pharmaceuticals RCKT Stock Holding History

Wealth Enhancement Trust Services’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.57K	Buy	+459	New	+$1.53K	﹤0.01%	1036

Other funds holding RCKT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Wealth Enhancement Trust Services's RCKT Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Rocket Pharmaceuticals (RCKT) in Q2 2026: 459 shares worth $1.57K. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings.

101 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Wealth Enhancement Trust Services held 459 shares of Rocket Pharmaceuticals worth $1.57K as of Q2 2026.
Rocket Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Rocket Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1036 holding.
101 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.